Caris Life Sciences (NASDAQ:CAI) Stock Rating Lowered by Wall Street Zen

Caris Life Sciences (NASDAQ:CAI) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Caris Life Sciences Stock Up 1.9%

Shares of CAI stock opened at $28.86 on Friday.

About Caris Life Sciences

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.